Literature DB >> 24473944

Dornase alpha use in patients with cystic fibrosis.

Paulo José C Marostica1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24473944      PMCID： PMC4183042          DOI： 10.1590/S0103-05822013000400001

Source DB:  PubMed          Journal:  Rev Paul Pediatr        ISSN： 0103-0582


× No keyword cloud information.
  13 in total

1.  Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis.

Authors:  W S CHERNICK; G J BARBERO
Journal:  Pediatrics       Date:  1959-11       Impact factor: 7.124

2.  Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.

Authors:  K McCoy; S Hamilton; C Johnson
Journal:  Chest       Date:  1996-10       Impact factor: 9.410

3.  A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.

Authors:  J M Quan; H A Tiddens; J P Sy; S G McKenzie; M D Montgomery; P J Robinson; M E Wohl; M W Konstan
Journal:  J Pediatr       Date:  2001-12       Impact factor: 4.406

4.  Dornase alfa improves the health-related quality of life among Brazilian patients with cystic fibrosis--a one-year prospective study.

Authors:  Tatiana Rozov; Viviane Ziebell de Oliveira; Maria Angélica Santana; Fabíola Villac Adde; Rita Heloisa Mendes; Ilma Aparecida Paschoal; Francisco J Caldeira Reis; Laurinda Yoko Shinzato Higa; Antonio Carlos de Castro Toledo; Márcia Pahl
Journal:  Pediatr Pulmonol       Date:  2010-09

Review 5.  Dornase alfa for cystic fibrosis.

Authors:  Ashley P Jones; Colin Wallis
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

6.  DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha.

Authors:  F Ratjen; K Paul; S van Koningsbruggen; S Breitenstein; E Rietschel; W Nikolaizik
Journal:  Pediatr Pulmonol       Date:  2005-01

7.  Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis.

Authors:  Terry E Robinson; Michael L Goris; Hongyun J Zhu; Xiaorong Chen; Prache Bhise; Farzana Sheikh; Richard B Moss
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

8.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

Authors:  H J Fuchs; D S Borowitz; D H Christiansen; E M Morris; M L Nash; B W Ramsey; B J Rosenstein; A L Smith; M E Wohl
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

Review 9.  Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus.

Authors:  Harry Heijerman; Elsbeth Westerman; Steven Conway; Daan Touw; Gerd Döring
Journal:  J Cyst Fibros       Date:  2009-06-25       Impact factor: 5.482

10.  Incidence of cystic fibrosis in five different states of Brazil as determined by screening of p.F508del, mutation at the CFTR gene in newborns and patients.

Authors:  Salmo Raskin; Lilian Pereira-Ferrari; Francisco Caldeira Reis; Fernando Abreu; Paulo Marostica; Tatiana Rozov; Joselina Cardieri; Norberto Ludwig; Lairton Valentin; Nelson Augusto Rosario-Filho; Eurico Camargo Neto; Eduardo Lewis; Roberto Giugliani; Edna Maria Albuquerque Diniz; Lodercio Culpi; John Atlas Phillip; Ranajit Chakraborty
Journal:  J Cyst Fibros       Date:  2007-06-04       Impact factor: 5.482
View more
  1 in total

1.  Rating of Perceived Exertion in Three-Minute Step Test in Children with Cystic Fibrosis.

Authors:  Amanda P Silva; Erika V Araujo; Igor P Machado; Livia F Alves; Marcos F DA Silva Mello; Pedro Henrique DE A Silva; Isabella R Dias; Viviane Soares
Journal:  Int J Exerc Sci       Date:  2021-04-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.